Clinical observation of oxycodone hydrochloride sustained-release tablets on neuropathic pain in patients with primary lung cancer during radiotherapy and chemotherapy
Objective To investigate the clinical effect of oxycodone hydrochloride sustained-release tablets on neuropathic pain in patients with primary lung cancer during radiotherapy and chemotherapy.Methods From June 2019 to June 2022,108 patients with neuropathic pain who were treated in 3201 Hospital were collected for prospective study,and they were divided into control group(54 cases),12 h titration group(26 cases)and 24 h titration group(28 cases)according to random number table method.The control group was given oral morphine hydrochloride tablets,12 h titration group and 24 h titration group were given oral oxycodone hydrochloride sustained-release tablets.General data,pain relief rate and number of breakthrough pain at different time points after treatment,quality of sleep and quality of life before and after treatment,and incidence of adverse reactions were compared among the three groups.Results There were all no statistically significant differences in gender,age,TNM stage and numerical rating scale score among the three groups(all P＞0.05).The pain relief rates in the 12 h titration group and the 24 h titration group 1 d after treatment were both higher than that in the control group(both P＜0.05).There were statistically significant differences in the numbers of breakthrough pain 1,2 and 3 d after treatment among the three groups(all P＜0.05),the numbers of breakthrough pain 2,3 and 7 d after treatment were all less than that 1 d after treatment(all P＜0.05).The numbers of breakthrough pain in 12 h titration group and 24 h titration group were both less than those in control group 1,2 and 3 d after treatment,and that in the 12 h titration group was less than that in the 24 h titration group(all P＜0.05).There were no statistically significant differences in comparison of Pittsburgh sleep quality index(PSQI)and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative(EORTC QLQ-C15-PAL)scores among the three groups before treatment(both P＞0.05),but there were statistically significant differences in comparison of PSQI and EORTC QLQ-C15-PAL scores 7 d after treatment(both P＜0.05).There were no significant differences in the incidences of adverse reactions among the three groups(P＞0.05).Conclusion Oxycodone hydrochloride sustained-release tablets for neuropathic pain during radiotherapy and chemotherapy in patients with primary lung cancer,especially 12 h as titration dose adjustment treatment,can achieve good pain relief rate,reduce the number of breakthrough pain,and do not increase the incidence of adverse reactions,with high safety.
万方数据
维普
